Since NF1 serves as a negative regulator of RAS, the first protein in the MAPK signaling cascade, mutations that cause a loss of NF1 function have been implicated in constitutive MAPK activation and acquired resistance to BRAFi therapy in melanoma [62,83]. The gene discussed is NF1; the disease is melanoma.